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Protein transport between organelles is mediated by vesicles which must accurately dock and fuse with appropriate compartments. Over
the past several years a large number of long coiled-coil proteins have been identified on the Golgi and on endosomes, mostly as auto-
antigens in autoimmune disorders. Based on their restricted intracellular distributions and their predicted rod-like structure, these proteins
have been proposed to play a role in tethering vesicles to target organelles prior to fusion. However, such proteins may also play a structural
role, for example as components of a Golgi matrix, or as scaffolds for the assembly of other factors important for fusion. This review will
examine what is known about the function of these large coiled-coil proteins in membrane traffic.D 2003 Elsevier B.V. All rights reserved.Keywords: Coiled-coil; Vesicle tethering; Golgin; Golgi; Endosome; Rab GTPase1. Introduction
The eukaryotic secretory pathway is made up of a
number of distinct organelles through which macromole-
cules traffic. Anterograde and retrograde transport by means
of vesicles, and other carriers, allows organelles to commu-
nicate with one another while maintaining their individual
homeostasis. Maintenance of a complex network of distinct
organelles requires that vesicles only fuse with the correct
destination compartment. Thus, organelles must possess
docking and fusion machinery that allows specific recogni-
tion of incoming vesicles.
Initially, the specificity of vesicle targeting was thought
to be mediated by SNARE (soluble NSF-attachment pro-
teins (SNAP) receptors) proteins [1]. The SNARE hypoth-
esis proposes that the pairing of v-SNAREs on vesicles and
t-SNARES on target membranes is sufficient to ensure that
vesicles recognise and fuse only with the correct acceptor
compartments. However, evidence that SNAREs are not the
complete picture comes from a variety of sources. The
observations that SNARE–SNARE pairing can be promis-
cuous, and that both v- and t-SNAREs are found on
recycling vesicles lead to a conceptual problem of how they
can specify a particular compartment [2,3]. In addition,0167-4889/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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less homogeneously, while vesicle fusion is frequently
observed at ‘‘hot spots’’ or discrete loci. For example during
polarised growth in the yeast Saccharomyces cerevisiae the
syntaxins Sso1p and Sso2p are found evenly distributed
throughout the plasma membrane, while exocytic vesicles
fuse only at the bud tip [4]. Most strikingly, EM pictures of
nerve terminals treated with botulinum and tetanus toxins,
which selectively cleave SNARE proteins, show docked
vesicles remaining tightly associated with membranes [5].
Finally, when membrane fusion is reconstituted in vitro
using SNARE proteins alone, the rate is slower than that
observed in vivo, suggesting that additional factors must be
available in the cell which stimulate vesicle fusion, possibly
by stabilising vesicle docking [6]. Recently, a whole range
of proteins have been proposed to act prior to SNARE
protein assembly to increase the specificity or efficiency of
the initial attachment of vesicles, a process now known as
tethering [7,8].
Proteins which have emerged as candidate tethering
factors fall into two general classes; those which are compo-
nents of multi-subunit complexes such as the GARP/VFT
complex [9–11], the COG complex [12,13], the TRAPP
complex and the Exocyst [7], and those which belong to a
class of large coiled-coil proteins [14,15]. Unlike SNARE
proteins, putative tethering factors are quite heterogeneous in
sequence and structure, although certain similarities are now
becoming apparent. For example, some but not all, large
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and have been termed quatrefoil complexes [16]. In addition,
motifs have been identified that are shared by a number of
coiled-coil proteins, as will be discussed below. What is
apparent is that many of the proteins have clear homo-
logues in all eukaryotes so far examined. This high degree
of conservation implies an important role in some aspect of
cellular function, although in many cases the precise nature
of this role remains unclear. Since multi-subunit complexes
have recently been reviewed elsewhere [7,16], this article
will examine the evidence to link large coiled-coil proteins
with the process of vesicle tethering and other aspects of
membrane traffic. In particular we will concentrate on the
large coiled-coil proteins of the Golgi and of endosomes,
where most of these proteins have been found. As yet, no
role has been proposed for large coiled-coil proteins in
membrane traffic at other compartments such as the ER
and the plasma membrane. A possible exception is the
neuronal synapse, where Rim1, a protein that plays a role
in priming synaptic vesicles for fusion, is localised to its
site of action by CAST, a neurone-specific, long coiled-coil
protein (reviewed in Refs. [17–19]). However, this review
will concentrate on proteins of the general trafficking
pathways.Fig. 1. Long coiled-coil proteins of the Golgi and of endosomes. Schematic repr
overall structures. Coiled-coil domains are shown in grey. Domains important for2. Coiled-coil proteins as potential vesicle tethers
Genes encoding coiled-coil proteins comprise roughly
5% of the coding sequences of a typical eukaryotic genome,
implying an involvement in numerous cellular processes
[20,21]. Coiled-coils are autonomous folding units consist-
ing of at least two a-helices that wrap around each other
with a slight left-handed superhelical twist [22]. The amino
acid sequence which gives rise to this structure consists of a
repeat of seven residues, termed a heptad repeat, in which
positions 1 and 4 of the sequence are usually hydrophobic
[23,24]. Such coiled-coils typically form rod-like structures,
and 100 amino acid residues is sufficient when dimerised to
extend about 15 nm.
A large number of long coiled-coil proteins have been
identified on the Golgi and endosomes, and the current set
for human cells is illustrated in Fig. 1 and Table 1. Most of
these proteins were not identified by functional assays, but
rather by indirect means often as antigens recognised by
sera from patients with autoimmune diseases, or as poten-
tially erroneous interactions arising from yeast two-hybrid
screens. Therefore, their potential role in membrane traffic
has often been inferred simply from their organelle-specific
location and their structure. Long rod-like molecules areesentations of known coiled-coil proteins, showing their relative sizes and
protein function or subcellular targeting are also indicated.
Table 1
Human long coiled-coil proteins proposed to play a role in membrane
traffic




TMD Giantin Macrogolgin 3260 – COY1
GCP364
GCP372
Golgin-84 731 CG17785 –
CASP 678 – –
GRIP Golgin-245 p230 2230 CG3493 IMH1
Golgin-97 767 CG4840
GCC88 GCC1 775 CG10703
GCC185 KIAA0336 1684a CG3532
Others p115 TAP 962 CG1422 USO1
GMAP210 Trip230 1979 CG7821 –
TMF1 ARA160 1093 CG4557 SGM1
Golgin-45 JEM-1 400 CG9356 –
GM130 Golgin-95 990 CG11061 –
Golgin-67 631 – –
Golgin-160 MEA2 1498 – RUD3?b
Endosomes
EEA1 p162 1410 – –
Rabaptin-5 Rabaptin-4 862 CG4030c –
Rabip4 RUFY1 606 CG31064 –
a GCC185 has been reported to be 1583 residues in length [101], but
our examination of ESTs suggests that it has an additional 101 residues at
the N terminus.
b Rud3p has been noted as being related to mammalian golgin-160 [78],
but this is over the coiled-coil regions of the proteins.
c Fly protein CG4030 has an FYVE domain at its C terminus that is
absent in the putative mammalian homologues.
Fig. 2. Possible roles for long coiled-coil proteins in the secretory pathway.
Coiled-coil proteins have been implicated in both heterotypic vesicle
tethering (A) and homotypic tethering of compartments (B). In addition,
coiled-coil proteins may form a meshwork over the surface of organelles
(C), which could mediate the selectivity of tethering by retaining or
repelling vesicles, and/or play a structural or ‘matrix’ role. Coiled-coil
proteins have also been suggested to form scaffolds or platforms for the
assembly of other factors required for membrane fusion (D).
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membranes at a distance, either for structural purposes or to
capture transport vesicles in the proximity of an organelle
prior to fusion. As illustrated in Fig. 2, several roles of this
type have been suggested for these proteins. Indeed, with
such a number and diversity of proteins, it is of course
possible that they do not all have the same type of function.
Most of these proteins are peripheral membrane pro-
teins, and most have been found to be associated with the
Golgi (termed ‘‘golgins’’) or with endosomes (Fig. 3) [25–
28]. This restriction to just a subset of organelles may be a
clue as to their precise role, and is in contrast to the large
multi-subunit complexes, which are found on most organ-
elles [16]. Perhaps coiled-coil proteins are specifically
localised to organelles where a high degree of vesicle
transport necessitates the actions of more than one tether-
ing factor. Indeed, the proposed rod-like structure of
coiled-coil proteins may enable them to assemble into
arrays along a membrane, increasing their local concentra-
tion. This tight meshwork of tethers could then act to
ensure that vesicles are selectively captured or repelled at a
particular membrane.
Examination of the surface of the mammalian Golgi by
freeze fracture electron microscopy has provided evidence
for the existence of fibrous elements, which may representcoiled-coil proteins, associated with vesicles and between
Golgi stacks [29]. Usually more than one of these elements
is observed making contact with a given vesicle. Such
multivalent interactions might be required to add specificity
to the tethering process, in that several proteins may be
needed to act together to capture a vesicle via a number of
weaker individual interactions. This could, perhaps, account
for the high degree of redundancy which seems evident in
many transport steps (see below, Sections 3.1 and 3.4), and
may also explain those cases where loss or mutation of one
tethering factor can be compensated for by overexpression
of another, or by overexpression of putative downstream
components such as SNAREs.
Secretory pathway coiled-coil proteins often have dis-
crete domains at their N or C termini, which may mediate
organelle-specific targeting or interactions with other pro-
teins. In addition, many of the proteins have small stretches
of non-coiled-coil sequence interspersed among the coiled-
coil regions which could act as hinges, enabling vesicles
docked at one end of the tether to be physically moved
closer to the membrane via some sort of mechanical action.
Moreover, the coiled-coiled structure requires that the pro-
teins either multimerise with themselves to form homo-
dimers or other oligomers, or form heterodimers with other
proteins. In theory these associations may be in parallel or
anti-parallel orientations, or as recently described for the
Rad50 zinc hook protein, coiled-coil proteins can fold in
half so that their N and C termini are in close apposition
[30]. However, as discussed below, all putative tethering
factors examined so far exist as parallel homodimers.
Fig. 3. Location of known long coiled-coil proteins in the mammalian
secretory pathway. Individual proteins are indicated next to those
compartments in which they have been localised, or in which a function
has been defined. Coiled-coil proteins from S. cerevisiae have also been
included and are shown in brackets and italics.
A.K. Gillingham, S. Munro / Biochimica et Biophysica Acta 1641 (2003) 71–8574Dimerisation of identical domains at the N or C termini may
be required to increase avidity for a specific binding partner.
As well as their role in vesicle tethering, large coiled-coil
proteins have been implicated in the assembly of a Golgi
‘‘matrix’’ or scaffold in mammalian cells [15,31]. This
matrix has been proposed by different studies to consist
either of members of the GRASP and ‘‘golgin’’ families
(Section 3.1), or of a spectrin/ankyrin meshwork [15]. Of
course vesicle tethering and maintenance of Golgi structure
are not mutually exclusive functions, since the latter can be
thought of as the tethering together of two compartments,
either with, or without, subsequent fusion. It is important to
note that some fungi and yeast, including S. cerevisiae, have
a Golgi composed of separate compartments, which are not
stacked and as such are unlikely to require the formation of
a Golgi matrix that facilitates stacking. S. cerevisiae does,
however, contain homologues of many of the proteins
implicated in the formation of the mammalian Golgi matrix,
implying that they perform functions besides their structural
role in stacking. These functions may include the formation
of a meshwork over the surface of the organelle which could
‘‘sample’’ incoming vesicles.Thus, the structure of large coiled-coil proteins appears
well suited to their serving a number of roles, but in
particular that of vesicle tethers, attaching to organelles via
their non-coiled-coil domains and extending into the cyto-
plasm to capture incoming vesicles. So what is the evidence?3. ER to Golgi and intra-Golgi traffic
3.1. p115, GM130 and giantin
3.1.1. p115
p115 was initially identified as a factor required in an in
vitro assay that reconstituted intra-Golgi vesicular transport
[32]. It is a 115-kDa peripheral membrane protein localised
predominantly to the cis-Golgi, and to structures between
the ER and the Golgi known as vesicular tubular clusters
(VTCs) [32,33]. Rotary shadowing shows that p115 is an
elongated homodimer with two globular N-terminal head
domains [34]. These head domains are unusually large
compared to the N-terminal regions of other Golgi coiled-
coil proteins, and it seems likely that they have a key role in
the function of p115, although so far this role remains
unclear. The tail domain of p115 is predicted to form four
stretches of coiled-coils (CC1–4) with a length of about 45
nm. Analysis of detergent solubilised Golgi membranes
revealed interactions between p115 and two other major
protein species, p130 and p400 [35]. These proteins were
subsequently identified as GM130 and giantin, and are now
discussed.
3.1.2. GM130 and GRASP65
GM130, also known as golgin-95, was identified as a
binding partner for p115 by Western blotting [35]. It is a
component of a TritonX-100 insoluble Golgi ‘‘matrix’’, and
binds to p115 via its first 75 amino acids [35]. GM130
associates with Golgi membranes by an interaction between
its C terminus and the protein GRASP65, a 65-kDa protein
involved in the reassembly of Golgi stacks following
mitosis (Fig. 4) [36,37]. Deletion analysis localises the
binding site for GRASP65 to the extreme C terminus of
GM130, and it comprises a short region ending in four
hydrophobic residues. Indeed, a fusion of green fluorescent
protein (GFP) to the last 170 amino acids of GM130 is
specifically targeted to the Golgi apparatus [37]. GRASP65
attaches to membranes via an N-terminal myristate anchor,
although other factors must be responsible for specifying a
Golgi localisation, since in theory a myristoylated protein
can associate with any available membrane [36]. The first
202 amino acids of GRASP65 target GFP to the Golgi,
although mutation of Gly2, which prevents myristoylation,
abolishes targeting.
GRASP65 itself contains two repeats that are distantly
related to the PDZ domain that mediates a number of
protein–protein interactions. The binding site for GM130









Fig. 4. The interactions between Golgi coiled-coil proteins that have been
proposed to mediate the tethering of COPI vesicles to the early Golgi
[39,56]. Giantin on COPI vesicles binds to GM130 on the Golgi membrane
via p115. GM130 is itself localised to the cis-Golgi by interaction with
GRASP65, which attaches to membrane via an N-terminal myristate
anchor. Both p115 and GM130 have been shown to interact with the small
GTPase Rab1. It should be noted that one study has reported that giantin
and GM130 compete for the same binding site on p115 [42].
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acids 194–201 in the rat sequence), and this region contains
the sequence GYGY, which is very similar to the conserved
binding site motif of the PDZ domain, GLGF [37,38].
3.1.3. Giantin
Giantin, also known as macrogolgin or GCP372, is the
second p115-binding partner, p400 [39]. It was first identi-
fied using monoclonal antibodies raised against Golgi
membranes, and cloning and sequencing showed it to be a
very large (400 kDa) type II integral membrane protein with
a C-terminal transmembrane domain (TMD) and the major-
ity of its mass projecting into the cytoplasm [25,40]. Giantin
is found both at the rims of the Golgi stacks and on COPI
vesicles [39]. The binding site for p115 on giantin has been
mapped to the N-terminal 448 amino acids [41].
3.1.4. Functional analysis of p115, giantin and GM130
So what are the functions of p115, GM130 and giantin?
The presence of giantin on COPI vesicles, the length of its
coiled-coil domain and the localisation of GM130 and p115
to membranes make them good candidates to act together to
tether COPI vesicles on to the Golgi. Indeed it has been
proposed that this type of long tether may enable vesicles
budding at one cisterna to become loosely attached to an
adjacent cisterna, preventing them from migrating away
from the vicinity of the Golgi [39]. In support of this model
are experiments which show that giantin on COPI vesicles
can be cross-linked to p115, and that binding of p115 to
COPI vesicles is inhibited by pre-incubation with anti-
giantin antibodies. An in vitro vesicle docking assay shows
that increasing the amount of added p115 increases the rate
of COPI vesicle docking. Furthermore, pre-incubation of
COPI vesicles with anti-giantin antibodies inhibits docking,
but pre-incubation of Golgi membranes has no effect. In
contrast, pre-incubation of Golgi membranes, but notvesicles, with anti-GM130 antibodies blocks docking [39].
Collectively this data suggests a model in which giantin on
COPI vesicles is bound to GM130 on Golgi membranes
with p115 acting as a linker (Fig. 4) [39].
Although the above experiments appear to show quite
clearly the interactions between giantin, p115 and GM130,
there is some debate. A study by Linstedt et al. [42] suggests
that GM130 and giantin actually compete for the same
binding site on p115. Furthermore, using antibodies against
p115, GM130 and giantin and an in vitro transport assay,
vesicle trafficking between the ER and the Golgi has been
dissected to show that the three proteins act at temporally
distinct stages; p115 antibody inhibition occurring at the
level of VTCs, and GM130 and giantin antibody inhibition
occurring at the Golgi [43], although this does not exclude
p115 from also acting in later steps in the Golgi. Further-
more, analysis of the kinetics of inhibition suggests that
GM130 is required prior to giantin, implying that they may
not function simultaneously [43]. GM130 and giantin also
localise to different regions of the Golgi, the majority of
GM130 is found at the cis-face of the stack, while giantin is
found predominantly at the Golgi rims. One possible expla-
nation for this is that giantin plays a dual role in Golgi
transport, playing both an essential role in a post-GM130
step, but an additional role in a GM130-dependent step, in
which it is not essential. In this respect it is interesting to
note that two other coiled-coil, integral membrane proteins
with TMDs related to that of giantin have recently been
identified (golgin-84 and CASP, see Section 3.3). These
proteins may be able to substitute for giantin at the GM130-
mediated step, although no direct evidence for this has been
reported.
Since p115 is a peripheral membrane protein recruited to
the Golgi by GM130, and since giantin on COPI vesicles
apparently enters them passively as it is present at the same
density as on Golgi membranes [39], the obvious question is
what is different about giantin on cisternae from giantin on
COPI vesicles, as only the latter appears to be a receptor for
p115. It is conceivable that the association of additional
proteins with stack-localised giantin, for example GCP60
(Section 3.1.7), enables the cell to differentiate between the
two giantin populations.
In mammalian cells the Golgi apparatus undergoes frag-
mentation and reassembly during mitosis, and inhibition of
the action of p115 in docking of COPI vesicles appears to
play an important role in this process [44,45]. Reduction of
p115 to below detectable levels by antibody induced pro-
teasome-mediated degradation, leads to Golgi breakdown
and an increase in vesicles similar to the changes observed
during mitosis [46]. The inhibition of p115 action during
mitosis appears to be mediated by modification of GM130
during the cell cycle. At the G2/M transition, GM130 is
phosphorylated by cyclin-dependent kinase I [47]. This
reduces the affinity of GM130 for p115, which results in a
loss of p115 from Golgi membranes, and an accumulation of
COPI vesicles in the cytoplasm. This, ultimately, results in
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tinue to bud but cannot fuse [35,45]. This can be recapit-
ulated in tissue culture cells, by microinjecting an N-
terminal peptide of GM130 corresponding to the p115
binding site. This peptide blocks the association of p115
with Golgi membranes and leads to an accumulation of
vesicles. Under these conditions, protein transport is re-
duced but not completely blocked, suggesting that alterna-
tive pathways may be utilised [48].
3.1.5. The association of p115 with SNAREs
Is the tethering process coupled to fusion? Analysis of
the sequence of p115 has suggested the presence of a
degenerate SNARE motif in coiled-coil-1 [49]. When this
region was used to probe detergent solubilised Golgi
extracts, interactions were identified with the SNARE
proteins involved in intra-Golgi transport, i.e. syntaxin 5,
GOS28, GHS15, Ykt6, rSec22 and membrin, as well as with
the syntaxin 5-binding protein Sly1 [49]. In an in vitro assay
to measure the formation of syntaxin 5-containing SNARE
complexes, sub-stoichiometric amounts of p115 stimulated
the formation of complexes. In addition, p115 could be
removed from the resulting complexes without affecting
their integrity. These observations suggest that p115 may
catalyse the formation of specific SNARE bundles during
docking and fusion of transport vesicles to the Golgi [49].
How could p115 act to stimulate SNARE assembly? It
has been suggested that p115 reduces the activation energy
for SNARE complex formation, or stabilises an assembly
intermediate, perhaps playing a similar role to complexin,
which binds in the groove of the syntaxin 1:SNAP23:VAMP
SNARE bundle, thereby stabilising it [49,50]. p115 binds to
the cytoplasmic domains of both syntaxin 5 and GS28, but
does not bind to SNARE proteins that are involved in post-
Golgi transport steps (e.g. syntaxin 1), indicating a degree of
specificity in p115’s interactions with SNAREs [49]. None-
theless, it should be noted that the analysis of SNARE
interactions is made particularly challenging by the fact that
the a-helical domains in SNAREs that form the SNARE
bundle are unfolded prior to assembly, which means they
have a propensity to bind to any protein which can stabilise
the formation of an a-helix [51,52].
3.1.6. The association of p115, GM130 and Rab proteins
In addition to its role in COPI vesicle transport within the
Golgi, p115 is also a key factor in the tethering of ER-
derived COPII vesicles to the Golgi. Indeed, inhibition of
p115 binding to COPII vesicles prevents them from docking
in an in vitro assay [53,54]. Along with tethering factors,
members of the Rab family of small GTPases have also
been implicated in the docking of vesicles with membranes
[55]. Recently, Allan et al. [54] showed that p115 binds to
Rab1-GTP, and that this is important for recruiting p115 into
a cis-SNARE complex on COPII vesicles (Fig. 4).
In addition to p115, the GM130:GRASP65 complex is
also a Rab1 effector, binding to Rab1-GTP in a p115independent manner (Fig. 4). This binding is required for
COPII vesicle docking or fusion at the cis-Golgi, presum-
ably at a step downstream of Rab1-p115 tethering [56,57].
One interesting observation is that GM130 and GRASP65
remain on membranes in the presence of Rab-GDI, whereas
most Rab effectors, including p115, are extracted from
membranes under these conditions. Thus one role of Rab1
may be to co-ordinate budding on donor membranes, with
docking and fusion at the acceptor compartment, by inter-
action with sequential tethers [56].
The S. cerevisiae homologue of Rab1 is Ypt1p, a protein
localised to vesicles and Golgi membranes. Using an in
vitro fusion assay, and a temperature sensitive allele of
Ypt1p that can block ER to Golgi transport in vivo, Cao
and Barlowe [58] dissected the role of Ypt1p on vesicles and
on the Golgi. Vesicles bearing mutated Ypt1p were fusion-
competent but acceptor membranes containing the same
mutation were not, implying an asymmetry in the function
of Ypt1p [58]. Furthermore, a TMD-anchored chimera of
Ypt1p, restricted to the acceptor compartment, could support
fusion of vesicles depleted of Ypt1p [58]. However, several
things remain unclear. How is Uso1p (the S. cerevisiae
homologue of p115, see below), or indeed any other tether,
attached to vesicles if this is not mediated by Ypt1p? And
how is the Ypt1p on vesicles distinguished from the Ypt1p
on acceptor membranes? In mammalian cells, perhaps, the
GDI-insensitivity of GM130 means that Rab1 (the Ypt1p
homologue) has a longer residence time on acceptor com-
partments than on vesicles, but this does not explain the
paradox in yeast. Presumably other proteins, either on
vesicles or on the Golgi, play a role in specifying the
identity of the two membranes.
3.1.7. Giantin interacting proteins
In addition to p115, other proteins have been identified
which interact with giantin; one such protein is GCP60
[59,60]. GCP60 was isolated in a yeast two-hybrid screen
using the cytoplasmic C-terminal region of giantin as bait
[59,60]. It is a ubiquitously expressed peripheral membrane
protein containing a domain related to acyl-CoA binding
proteins, and a C-terminal GOLD domain, a feature of
unknown function found in several otherwise unrelated
proteins [60,61]. The exact role of GCP60 is unclear but it
localises to Golgi rims via its C terminus, the region of the
protein that also binds giantin. Overexpression of GCP60
results in Golgi disassembly and blocks transport of the viral
membrane protein VSV-G at the point of ER exit. Homo-
logues of GCP60 have been identified in C. elegans and
Drosophila (but not in yeasts) which suggests an additional
role for GCP60, since neither worms nor flies contain an
obvious homologue of giantin [60].
3.1.8. Golgin-67
The golgin-67 gene was serendipitously isolated in the
process of screening a human cDNA expression library with
antibodies against SAM68, an otherwise unrelated protein
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a predicted size of 51.4 kDa but the native protein runs as a
67-kDa species [62]. Antibodies raised against recombinant
golgin-67 decorate the Golgi apparatus, and the C terminus
of golgin-67 is essential for Golgi targeting [62]. This region
was reported to encode a TMD, but the sequence does not
appear particularly hydrophobic, and current TMD predic-
tion programmes (e.g. TMHMM 2.0) do not suggest the
existence of a TMD. There is, however, an unusual cysteine-
rich sequence (CCVPCFC) very close to the C terminus
which could act as a lipidated membrane anchor.
Golgin-67 is related to GM130 across much of its length
[62,63] but does not contain the binding site for GRASP65
found at the C terminus of GM130. Database analysis
reveals that golgin-67 is part of an extensive family of
GM130-like genes in humans, many of which are also found
in the EST database and are therefore not pseudogenes.
Indeed, at least 10 copies of a short duplicated region, each
containing a GM130-related protein, are found on chromo-
some 15 [64]. The exact function of these GM130-like
proteins remains to be established, but it is interesting to
note that duplication of this gene locus appears to be a
recent event in evolution, since it is not present in mouse
which only has GM130 itself.
3.2. S. cerevisiae Uso1p
Uso1p is the S. cerevisiae homologue of p115. It is an
essential 1790-amino-acid (200-kDa) protein, which has
been shown by electron microscopy to consist of a globular
head domain and a long (approximately 150 nm) C-terminal
a-helical coiled-coil with some hinge regions [65]. Uso1p
and p115 share homology in their head domain but the
coiled-coil region of Uso1p is at least twice the size of that
of p115. Since yeasts do not appear to have an obvious
homologue of GM130, and since the C-terminal region of
Uso1p is, perhaps, related to GM130, it has been suggested
that Uso1p represents a fusion of p115 and GM130 [35]. It
will be interesting to determine whether the recently iden-
tified S. cerevisiae homologue of GRASP65, encoded by the
nonessential gene GRH1, associates with Uso1p in a similar
manner to that seen with GM130 and GRASP65 in mam-
malian cells [37].
ER–Golgi transport in yeast can be reconstituted in vitro
by incubating salt-washed membranes with purified COPII,
Uso1p, LMA1, ATP and GTP [53]. In this assay COPII
vesicles that have budded from the ER only dock with Golgi
membranes upon addition of Uso1p. Vesicle docking is
sensitive to GDI (Sec19p in S. cerevisiae) which removes
Ypt1p (yeast Rab1) from both vesicles andGolgi membranes.
In addition, the degree of membrane-bound Uso1p correlates
closely with the amount of membrane bound Ypt1p, suggest-
ing that Ypt1p is important for Uso1p targeting [8].
Genetic evidence from yeast demonstrates that, as
expected, SNARE proteins act downstream of both Uso1p
and Ypt1p. Temperature-sensitive mutations in the yeastSNAREs Sed5p, Bet1p, Bos1p and the syntaxin-5 interact-
ing protein Sly1p do not prevent Uso1p mediated tethering
of vesicles, but block ER–Golgi transport by inhibiting
fusion [66]. Interestingly, overexpression of the same
SNAREs rescues deletion of Ypt1p and temperature-sensi-
tive mutations in Uso1p [66]. Therefore, tethering is depen-
dent on Uso1p and Ypt1p but overexpression of SNAREs
can bypass this requirement. This latter observation is
perhaps due to weak inefficient SNARE-mediated interac-
tions with the vesicle which, when present in increased
numbers, can overcome the need for a semi-docked ‘‘teth-
ered’’ intermediate [8,53,66].
In addition to its putative role in vesicle tethering,
Uso1p may also play a role in protein sorting during the
formation of COPII vesicle on the ER [67]. Morsomme
and Reizman [67] showed recently, using an assay which
reconstitutes ER-derived vesicle budding in vitro, that
sorting of GPI-anchored proteins from non-GPI-anchored
proteins is defective in a temperature-sensitive mutant of
USO1 (uso1-1).
3.3. Integral membrane proteins related to giantin
Two integral membrane proteins have recently been
identified which share sequence homology with giantin in
their C-terminal TMDs, and which localise to the cis/medial
Golgi. These proteins are known as golgin-84 [68] and
CASP (CDP/cut alternatively spliced protein) [69]. Golgin-
84 is an 84-kDa protein, which is predicted to form coiled-
coils over the majority of its length, and is capable of
forming dimers as shown by chemical cross-linking. Inter-
estingly, an oncogenic chromosome translocation has been
identified that results in the coiled-coil domain of golgin-84
becoming fused to the cytoplasmic portion of the receptor
tyrosine kinase c-ret [68]. Presumably, dimerisation by the
golgin-84 derived sequence leads to constitutive activation
of the kinase domain.
Like golgin-84, CASP is a large coiled-coil protein,
which shares homology with giantin in its C-terminal
TMD. Indeed, all three of these proteins possess conserved
histidine and tyrosine residues within this region [69]. In
contrast to the other two proteins, CASP has a clear
homologue in S. cerevisiae, known as Coy1p [69]. Indeed,
all eukaryotes so far examined have at least one of these
related proteins, although only mammals have all three,
suggesting that they might all be involved in the same
transport steps and are able to compensate for one another.
The identification of Coy1p in yeast has allowed genetic
analysis of the protein which has revealed a genetic inter-
action with the yeast SNARE proteins Gos1p (the S.
cerevisiae homologue of GS28) and Sec22p. Mutation of
the conserved histidine residue in the TMD of Coy1p does
not affect the localisation of HA-tagged Coy1p but does
disrupt the genetic interaction with Gos1p. Therefore the
TMD of CASP (and by analogy those of giantin and golgin-
84) may mediate cross-talk between events at the cytoplas-
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ring in the membrane.
3.4. Golgin-160
Golgin-160, also known as GCP170, was identified by
screening a human cDNA library with an antiserum from a
patient with the autoimmune disorder systemic lupus eryth-
ematosus, and was shown to reside on the cis-Golgi com-
partment [26,70]. Golgin-160 is predicted to form coiled-
coils over two thirds of its length, with an N-terminal head
domain (residues 172–257) that is responsible for targeting
the protein to Golgi membranes. Golgin-160 does not have
any clear homologues in Drosophila or C. elegans, and
indeed the abundance of the murine homologue of golgin-
160 (MEA-2) in testis may indicate a specialised function in
this tissue. Homozygotes of a transgenic mouse line in
which golgin-160/MEA-2 is disrupted are sterile due to an
apoptotic degeneration of spermatocytes [71,72]. Since the
Golgi apparatus is thought play an important role in acro-
some formation, these results implicate golgin-160 in this
process [71]. Interestingly, golgin-84 is also particularly
abundant in testis [68], suggesting that a number of golgins
may be required for acrosome formation.
3.5. GMAP-210
GMAP-210 was independently identified in a screen of
an expression library with a human auto-antiserum, and by
showing an apparent interaction with retinoblastoma protein
in a yeast two-hybrid screen [73,74]. On the basis of the
latter interaction, the protein was suggested to be a possible
coactivator of thyroid hormone receptor and so named
Trip230 [75], but subcellular localisation showed the protein
to be associated with the cis-side of the Golgi apparatus
[74]. Deletion analysis reveals that the C-terminal region of
GMAP-210, a region suggested to bind thyroid hormone
receptor, is responsible for Golgi targeting [75]. This region
was also reported to interact with the minus end of micro-
tubules [76], although the significance of this is unclear as
the intracellular distribution of the protein does not resemble
that of microtubule minus-ends. At present, the function of
GMAP-210 on the Golgi is unknown, and so possible
nuclear or microtubule binding roles cannot be formally
excluded. Overexpression of GMAP-210 induces an en-
largement of the Golgi apparatus and perturbations in the
microtubule network [74]. In addition, anterograde transport
of both a soluble form of alkaline phosphatase and the
integral membrane protein hemagglutinin between the ER
and the cis/medial Golgi stacks is inhibited, suggesting a
role in Golgi function [77].
3.6. S. cerevisiae Rud3p
In addition to Uso1p and Coy1p, a further S. cerevisiae
coiled-coil protein has been implicated in membrane trafficprocesses in the early Golgi. This is Rud3p, also known as
Grp1p, which was independently identified in two genetic
screens for proteins which, when overexpressed, could
suppress the temperature-sensitive growth defects of the
mutants uso1-1 or sec34-2 [78,79]. These are both condi-
tional mutations in proteins proposed to be involved in
vesicle tethering in the Golgi, and overexpression of Rud3p
can also suppress several other mutations that inhibit
membrane traffic in the early Golgi including sec35-1,
sec22-3 and bos1-1, strongly suggesting some role for
the protein in these processes [78]. Rud3p is a nonessential,
484-amino-acid, peripheral membrane protein with a mo-
lecular mass of 56 kDa, and is predicted to form a coiled-
coil, particularly in the central f 200-amino-acid region.
The coiled-coil region of Rud3p has been suggested to be
related to that of the mammalian Golgi protein, golgin-160,
but is also related to many other coiled-coil proteins in this
region [78]. At present no proteins have been identified
which interact with Rud3p, and its precise role remains
unclear.4. Medial Golgi transport steps
As well as transport to and from the cis-Golgi, transport
also occurs within the Golgi stack. At present it is still
debated whether vesicles traffic in an anterograde manner
between cisternae or whether cargo moves from the cis- to
trans-side of the Golgi by a process of cisternal maturation
[80,81]. What is clear is that retrograde transport within the
Golgi exists, and that this is mediated by COPI vesicles.
These vesicles are responsible for trafficking enzymes and
Golgi components back to their resident cisternae, ensuring
that they are not depleted at their site of action [82].
4.1. Golgin-45 and GRASP55
GRASP55, a homologue of GRASP65, is localised to the
medial Golgi where it is important for the maintenance of
the Golgi matrix and for Golgi re-stacking in vitro [83]. Like
GRASP65, GRASP55 appears to be a receptor for a coiled-
coil protein, in this case golgin-45, a protein with a central
coiled-coil region that is conserved in flies and worms, but
apparently not in yeasts. Golgin-45 was also identified in a
screen for genes up-regulated by retinoic acid treatment, and
termed JEM-1 [84]. Although JEM-1 was initially proposed
to be a potential nuclear cofactor, golgin-45 shows a clear
localisation to the Golgi apparatus. Depletion of golgin-45
from cells by RNA interference results in a marked redis-
tribution of the medial Golgi enzyme GlcNac transferase I
back to the ER, along with a disruption of early and medial
Golgi morphology [85]. In addition, transport of the marker
protein VSV-G is abrogated, and the protein remains in the
ER. Like other golgins, golgin-45 binds specifically to a
small GTPase protein, in this case Rab2, a GTPase impli-
cated in early Golgi transport [85,86].
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5.1. GRIP domain proteins
The GRIP domain is a sequence of approximately 50
residues, which is shared by a number of proteins, and has
been named according to the first letter of several of these
(golgin-97, Ran-binding protein 2a, Imh1 and p230/golgin-
245) [87–89]. This domain, predicted to form three short a-
helices, is sufficient to target GFP to the trans-Golgi. It
contains only one invariant residue, a tyrosine near the start
of the domain, which is critical for Golgi targeting in both
mammals and protists [90]. Mammalian GRIP domains
have been shown to bind to Rab6 on proteins blots, and
mutations which prevent Golgi targeting, also disrupt Rab6
binding [88]. However, Rab6 does not appear to be the only
small GTPase capable of binding to the GRIP domain, and
may not be the physiologically relevant interacting partner
(see below).
5.1.1. Golgin-245
Golgin-245, also known as p230, was identified in two
independent studies that probed cDNA libraries with sera
from patients with the autoimmune disorder Sjogrens syn-
drome [91,92]. The protein has 2230 amino acids with a
predicted molecular mass of 261 kDa, and Western blotting
with the original human sera detects a protein of 245 kDa
[91]. Immunogold labelling shows that golgin-245 specifi-
cally localises both to tubulovesicular structures and to
TGN-derived non-clathrin-coated vesicles, which do not
contain Rab6 [93,94]. Overexpression of the golgin-245
GRIP domain, which has the potential to displace endoge-
nous golgin-245, does not affect the number of vesicles
budding from the TGN. This implies that golgin-245 is not
involved in the budding process but may be required for
downstream events [93].
The localisation of golgin-245 to the trans-side of the
Golgi complex can be stimulated both by activation of
heteromeric G proteins using AlF4
, and by activation of
small G-proteins with GTPgS [94]. This implies a role for
GTPases in recruiting the GRIP domain to the Golgi. This
might be consistent with a role for Rab6, but recently Van
Valkenburgh et al. [95] reported that GRIP domain proteins
were among those isolated in a yeast two-hybrid screen
which used the activated form of the GTPase ARL1 as bait.
These GRIP domain proteins were golgin-245 and
RanBP2a, along with a small Golgi localised, coiled-coil
protein called SCOCO. ARL1 is a member of a family of
ARF-like GTPases which share about 50% identity with
ARF GTPases, and of which there are at least 10 in humans.
ARFs have a well-characterised role in vesicle coat recruit-
ment [55], but in contrast little is known about the function
of ARLs, although ARL1 has been found to be localized to
the Golgi apparatus [95–97]. Mutation of the conserved
tyrosine in the GRIP domain, responsible for Golgi target-
ing, disrupted the yeast two-hybrid interaction betweengolgin-245 and activated ARL1, indicating that the GRIP
domain is important for this interaction [95]. Moreover, it
has recently been shown in S. cerevisiae that Arl1p is
required for the Golgi targeting of the one S. cerevisiae
protein with a GRIP domain (Imh1p, see below), and that
the domain and the GTPase bind directly in a GTP-depen-
dent manner [98,99].
5.1.2. Golgin-97, GCC88 and GCC185
Golgin-97, like golgin-245, was also identified using
serum from a patient with Sjogrens syndrome to screen a
cDNA library [100]. Although little is known about its
function, golgin-97 has been implicated in vesicle tethering
based on its coiled-coil structure and the presence of its
GRIP domain, which is sufficient to target GFP to the trans-
side of the Golgi [87–89].
Database searching reveals two additional mammalian
proteins with predicted coiled-coil sequence and a C-termi-
nal GRIP domain, GCC88 and GCC185 (originally termed
GCC1 and KIAA0336, respectively) [101]. These proteins
are also localised to the TGN, and overexpression of
GCC88 results in the formation of electron-dense extensions
of this compartment, [101]. The human genome encodes a
fifth GRIP domain protein, RanBP2a, but this appears to be
the result of a recent gene duplication and rearrangement
that has attached the C terminus of GCC185 to the nuclear
transport protein RanBP2 and so its biological significance
is unclear.
In addition to the mammalian proteins described above,
many organisms have proteins with putative GRIP domains
[87–89]. Indeed the Drosophila genome appears to encode
four such proteins (Table 1), whereas one has been identi-
fied in each of yeast (Section 5.1.3), plants and protozoa
[90]. This conservation across species suggests an important
role for GRIP domain proteins in cellular function, and in
the case of higher eukaryotes, the conservation of four
distinct GRIP proteins suggests a possible diversity of roles.
5.1.3. S. cerevisiae Imh1p
Imh1p, also called Sys3p, is the only protein in the yeast
S. cerevisiae that contains a discernible GRIP domain. It is a
105-kDa, nonessential protein predicted to form coiled-coils
over most of its length [87–89,102]. It was independently
identified by two different laboratories as a suppressor of the
temperature sensitivity of a yeast strain lacking functional
Ypt6p (the yeast homologue of Rab6) [102,103]. Deletion of
both IMH1 and YPT6 leads to a severe growth defect or
inviability of the strain at all temperatures tested, an accu-
mulation of vesicles, and a defect in a-pheromone matura-
tion [102,103]. The latter effect is probably due to the
missorting of recycling Kex2p, a protease that is required
for a-pheromone processing [102]. In the absence of Imh1p
and Ypt6p, vesicles containing Kex2p returning to the Golgi
can no longer dock with membranes, and the protein is
therefore mistargeted to the vacuole where it is degraded.
Indeed, levels of Kex2p in strains in which both YPT6 and
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indicates a role for both Imh1p and Ypt6p in vesicle
tethering; however, as yet, no physical interaction between
these proteins has been found [102]. It may be that the two
proteins both contribute to the same process in a manner that
allows one or the other to be lost but not both. Alternatively,
it may be that the proteins act in distinct transport pathways
that are sufficiently related to be redundant under laboratory
growth conditions. As mentioned above, it has recently been
found that the Golgi targeting of Imh1p is mediated by a
direct association with the GTP-bound form of the GTPase
Arl1p [98,99].
5.1.4. TMF/ARA160 and S. cerevisiae Sgm1p
Recent biochemical studies have shown that activated
Ypt6p binds to the GARP/VFT complex, a putative vesicle
tethering complex required for the retrieval of late Golgi
proteins and also to another coiled-coil protein called
Sgm1p [9,10]. Sgm1p is a nonessential protein which
contains two substantial regions of predicted coiled-coil
[9]. At present, the exact function of Sgm1p remains
unknown, but the mammalian homologue TMF/ARA160
has recently been localised to the Golgi apparatus [104],
despite being originally proposed to be a transcription factor
[105,106].6. Endosomal transport steps
6.1. EEA1
As in the Golgi, long coiled-coil proteins appear to play
an important role in membrane fusion events in the endo-
somal system. The most well-characterised endosomal
tethering protein is EEA1, which was identified as an
autoantigen in subcutaneous systemic lupus erythematosus
[27,107]. It is predicted to consist mostly of coiled-coil,
and chemical cross-linking indicates that it forms homo-
dimers. EEA1 has been localised to early endosomes
(EEs), and by electron microscopy to filamentous material
that extends about 50 nm into the cytoplasm, but it is not
found on clathrin-coated vesicles (CCVs). EEA1 local-
isation has been further defined by the observation that it
appears only on a subset of EEs in polarised epithelial
cells, such as MDCK cells, where it appears to play a
specific role in basolateral endocytic sorting pathways
[108]. Even in nonpolarised cells such as fibroblasts,
EEA1 labels a subpopulation of endosomes distinct from
those targeted by a transfected apical marker protein,
endotubin. This restricted localisation implies that EEA1
may be important for specifying the directionality of
tethering and fusion [108].
Like some Golgi coiled-coil proteins, EEA1 interacts
with a member of the Rab family of GTPases, in particular
with the activated (GTP-bound) form of Rab5 which is
localised to endosomes [109]. EEA1 appears to contain twospatially distinct Rab5 binding sites, one at either end of the
protein [109]. Both appear to be functional, since a point
mutation in the N-terminal domain is sufficient to abrogate
Rab5 binding to this region, and the C-terminal Rab5
binding domain is 29% identical to the Rab5 binding
domain in Rabaptin-5, another Rab5 effector protein
[109,110]. However, Rab5 is not the sole determinant of
EEA1 targeting to membranes, since mutation of the Rab5
binding sites does not affect the localisation of EEA1 [111].
Moreover, Rab5 is not only located to early endosomes, but
is also found on the plasma membrane and on CCVs, while
EEA1 localisation is restricted to early endosomes. This
appears to be because the targeting of EEA1 is primarily
dependent on a second determinant, the phosphoinositide
PI(3)P [112]. Treatment of cells with the PI 3-kinase
inhibitor, wortmannin, leads to dissociation of EEA1 from
membranes [109]. The region of EEA1 responsible for
binding PI(3)P is a specialised form of the zinc finger RING
domain, known as the FYVE domain, a name derived from
the first four proteins in which it was identified (Fab1,
YOTB/ZK632.12, Vac1 and EEA1) [113–115].
The C-terminal FYVE domain of EEA1 alone is not
sufficient to target GFP to early endosomes. Instead, a
stretch of about 130 residues, including the FYVE domain,
the Rab5 binding site and a short stretch of coiled-coil
sequence, is required [113]. This additional sequence is
important for dimerisation of the C termini resulting in the
association of two FYVE domains that mediate binding.
Indeed, the affinity of a single FYVE domain for PI(3)P is
of the order of 130 AM, while by contrast, the affinity for
bivalent binding by the homodimer would be predicted to be
the square of this value, i.e. about 17 nM. This figure is
close to the experimentally observed value of 50 nM [116].
Thus bivalency of the FYVE domain serves to overcome
both the low affinity and selectivity for PI(3)P exhibited by
the monomeric domain. EEA1 is one of the few coiled-coil
proteins to be crystallised, at least in part. Crystallisation of
these proteins is inherently difficult due to the elongated
nature of their structure, but it has proven possible with the
C-terminal 123 residues of EEA that include the FYVE
domain. The structure of this region bound to I(1,3)P2
reveals an ordered parallel coiled-coil ending in a dyad
symmetric FYVE domain homodimer [117].
So what is the evidence that EEA1 is involved in mem-
brane tethering at the early endosome, and how is this
regulated? First, anti-EEA1 antiserum inhibits an in vitro
assay for early endosome fusion by 80% [109]. Likewise,
depletion of EEA1 from cytosol used in the assay results in a
decrease in endosome fusion that can be rescued by adding
back recombinant EEA1. As well as homotypic fusion, EEA1
also tethers CCVs derived by endocytosis from the plasma
membrane on to early endosomes [118]. Thus EEA1 appears
to play a role in specifying the target organelle for both
homotypic and heterotypic fusion. The specification of endo-
somal membranes by EEA1 is thus analogous to the speci-
fication of Golgi membranes by p115 for docking of both
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ing mitosis, i.e. homotypic Golgi fusion.
Since EEA1 is a long molecule with binding sites at both
ends, one can easily imagine that it binds to endosomes via
its C-terminal FYVE domain, and to Rab5 positive compart-
ments via its N terminus, bringing them into close apposi-
tion for fusion. The putative coiled-coils, which make up the
majority of EEA1, are interrupted by several proline–
glycine motifs, which may introduce flexible kinks close
to the N-terminal Rab5 binding site. One could therefore
envisage a scenario where a conformational change within
the flexible region of EEA1 brings the two membranes
closer together. One puzzling observation is that free EEA1
homodimers in the cytoplasm do not seem to bind to CCVs.
This may be because the clathrin coat blocks EEA1 binding
to the vesicle. However, this is unlikely since in an in vitro
assay, CCVs, which are uncoated by the actions of the
ATPase Hsc70, still do not bind EEA1 [118]. Thus an
alternative explanation is that the low affinity of the Rab5
interaction requires that EEA1 oligomerises on endosomal
membranes before CCV binding can be stabilised through
the engagement of multiple N-terminal Rab5 binding
domains [118].
Recently, the PI 3-kinase hVPS34 has been shown to be
a Rab5 effector. This may be one way of linking PI(3)P
production with Rab5 localisation. Furthermore, hVPS34 is
absent from CCVs, and thus may provide an insight into
the asymmetric localisation of EEA1. Of course this raises
the question of how hVPS34 is itself localised to EEs, and
there is evidence that this is mediated by association with
other factors such as Vps15p/p150 and beclin [119–121].
There is no clear homologue of EEA1 in S. cerevisiae. The
FYVE domain protein Vac1p, a protein involved in endo-
some and vacuole fusion, was initially proposed as the
yeast homologue; however, this protein appears more
closely related to the mammalian protein Rabenosyn-5
[122].
6.1.1. EEA1 interaction with SNAREs
As with the early Golgi tethering protein p115, EEA1 has
also been suggested to couple tethering with SNARE
engagement. In an in vitro fusion assay, addition of EEA1
alone is sufficient to support a minimal level of homotypic
endosome fusion [107]. One possibility is that EEA1 not
only acts as a kinetic tether, but also stimulates the forma-
tion of SNARE complexes.
A yeast two-hybrid approach, using full-length EEA1 as
bait and a number of SNAREs as prey, showed a specific
interaction between EEA1 and syntaxin 6 [123]. This
interaction was mediated by the C terminus of EEA1;
however, neither the Rab5-binding site nor the FYVE
domain alone was sufficient. GST-syntaxin 6 was shown
to bind EEA1, both from cytosol, as well as recombinant
protein, the latter result indicating a direct association [123].
Interestingly, Rab5-GTP and syntaxin 6 appear to compete
for binding to EEA1, implying that their binding sitespartially overlap. Thus EEA1 may mediate tethering via
sequential interaction with Rab5 and syntaxin 6.
In addition to syntaxin 6, other SNARE proteins have
been implicated in early endosome fusion. In particular, the
soluble domain of syntaxin 13 has been shown to specifi-
cally inhibit this process in vitro [124]. Furthermore, a direct
interaction between EEA1 and syntaxin 13 has been dem-
onstrated using a biosensor assay [124]. Interestingly, al-
though soluble syntaxin 6 had no effect on the in vitro
endosome assay, both syntaxin 6 and syntaxin 13 are
predicted to bind to approximately the same region of
EEA1 [123,124].
EEA1 has been suggested to exist on endosomal mem-
branes in a large oligomeric complex which contains the
Rab5 effectors Rabaptin-5, Rabex-5, as well as NSF, the
ATPase activity of which modulates assembly of the com-
plex [124]. How might this complex mediate or stimulate
fusion? One suggestion is that the formation of higher order
EEA1/NSF oligomers is analogous to the large oligomers
formed by viral glycoproteins, which mediate the formation
of a viral fusion pore [124], thus linking vesicle tethering
with fusion. Another possibility is that EEA1 simply pro-
vides a large platform for other proteins involved in fusion
to assemble. This may then allow local activation of
SNARE complexes containing syntaxin 13 and possibly
syntaxin 6.
6.2. Rabaptin-5
Rabaptin-5 is a large coiled-coil protein, which was
identified as a Rab5 effector using a yeast two-hybrid screen
[125]. It has two long regions predicted to form coiled-coils
separated by a flexible linker. Rabaptin-5 is recruited to
early endosomes from the cytosol in a Rab5-dependent
manner, and overexpression stimulates endosome fusion in
vivo [125,126]. Interestingly, Rabaptin-5 is not functional
by itself in an vitro endosome–endosome fusion assay and
in fact inhibits the assay [127]. This is because, in vivo, it is
found in a complex with another protein, known as Rabex-
5. Rabex-5 is a guanine nucleotide exchange factor for
Rab5, and has been proposed to link recruitment of Rabap-
tin-5 with the subsequent activation of Rab5 [127,128].
Indeed, overexpression of Rabex-5 can bypass the require-
ment for Rabaptin-5. Thus, Rabaptin-5 and Rabex-5 perhaps
create a region of activated Rab5 on early endosomes,
which may act as a target for incoming vesicles or as a
binding domain for other proteins involved in vesicle
docking.
Rabaptin-5 has a C-terminal Rab5 binding domain and
a distinct N-terminal Rab4 binding domain [129]. The
finding that Rabaptin-5 binds Rab4 is intriguing since
Rab4 is important for recycling from early endosomes to
the cell surface, while Rab5 is involved in endocytosis,
suggesting that Rabaptin-5 could be involved in co-ordi-
nating the actions of both these pathways at endosomes
[129].
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Rabip4 is a 600-amino-acid protein, which was identified
as an effector of Rab4 [130]. In addition to two regions of
coiled-coil, it contains an N-terminal RUN domain, through
which it associates with endosomes, and a C-terminal FYVE
domain [130,131]. As discussed earlier, FYVE domains
bind PI(3)P [115], while RUN domains are less well defined
but are found in various proteins whose functions are linked
to those of the Ras families of GTPases [132].
Co-expression of Rabip4 and activated Rab4 leads to the
expansion of early endosomes [130] and an increased co-
localisation of markers for sorting and recycling endosomes
[130]. Furthermore, the protein GLUT1, which normally
recycles through the plasma membrane, now accumulates
within the endosomal system [130]. This suggests that
Rabip4 may promote retrieval from recycling to sorting
endosomes; thus, overexpression causes components to be
trapped in a recycling loop between the two compartments,
and hence they become mixed.
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Cells undergoing apoptosis undergo a series of charac-
teristic changes including DNA cleavage, nuclear break-
down, blebbing, and fragmentation of organelles [133].
These events ultimately lead to the disintegration of cells
to form apoptotic bodies, which are engulfed by neighbour-
ing cells. As discussed earlier (Section 2), a number of
coiled-coil proteins thought to act as tethering proteins were
originally identified as autoantigens in systemic autoim-
mune diseases [25,26]. A number of these Golgi and endo-
somal autoantigens appear to be specific targets for the
proteolytic actions of caspases during apoptosis. The exact
purpose of these events remains to be established, but its is
interesting to speculate that cleavage of proteins responsible
for vesicle transport/docking would be an ideal way to
disassemble organelles in a controlled manner. This mech-
anism may be similar to that used during mitosis, where
phosphorylation of GM130 results in loss of p115 binding
to membranes which in turn inhibits fusion of COPI vesicles
with the Golgi [35,44]. However, there is at least a mech-
anistic difference in that GM130 remains unphosphorylated
during apoptosis [134].
7.1. Golgins
Both giantin and golgin-160 (Sections 3.1.3 and 3.4) are
susceptible to caspase cleavage during apoptosis [135,136].
Treatment of Jurkat cells with staurosporine to induce
apoptosis generates three specific giantin fragments and
two golgin-160 derived fragments. In contrast, golgin-97
and GM130 appear relatively resistant to cleavage under
these conditions. These results indicate that either a subset
of golgins are targets for caspases or that there are differ-ences in the kinetics of golgin degradation, and that giantin
and golgin-160 are early targets for caspases during apo-
ptosis [135]. Golgin-160 is acted upon by caspase-2, -3 and
-7. The first cleavage is mediated by caspase-2 and this
proteolytic event appears to be critical since blocking it by
mutation of the cleavage site, prevents the subsequent
actions of caspase-3 and -7, and delays Golgi fragmentation
[136]. Recently, a nuclear localisation signal (NLS) has
been identified in the N-terminal head domain of golgin-
160 [137]. During apoptosis, cleavage of golgin-160 results
in the release of fragments that are specifically imported
into the nucleus [137]. The function of these fragments
remains to be established, although it has been speculated
that they could regulate transcription during apoptosis. p115
is also cleaved by caspases during apoptosis, and like
golgin-160, the resulting C-terminal 30-kDa fragment spe-
cifically translocates into the nucleus [134]. Significantly,
expression of this C-terminal fragment also induces apo-
ptosis and leads to Golgi fragmentation, suggesting a role
for p115 in the propagation of the apoptotic signal [134].
Rosen and Casciola-Rosen [138] have proposed that mod-
ifications of auto-antigens during apoptosis may be crucial
for the generation of auto-antibodies in autoimmune disor-
ders. The alteration of coiled-coil proteins by cleavage
during apoptosis, along with their extended and repetitious
structure, may perhaps explain why so many have been
identified as antigens recognised by the sera of patients with
autoimmune diseases.
7.2. GRASP65
As well as the long coiled-coil proteins, it appears that
their membrane receptors can also be targets for caspases
during apoptosis. Recently, GRASP65 (Section 3.1.2) was
shown to be a specific target for caspase-3, being cleaved at
a conserved site close to the C terminus at an early stage in
apoptotic cell death [139]. Interestingly, expression of a
caspase-resistant mutant of GRASP65 partially delayed the
loss of integrity of the Golgi ribbon in apoptotic cells,
consistent with GRASP65 normally playing a role in the
maintenance of Golgi structure [139].
7.3. Rabaptin-5
Endosomal coiled-coil proteins are also targets for
caspases during apoptosis. As discussed above (Section
6.2), Rabaptin-5 consists of two large coiled-coil domains
linked by a non-coiled-coil region. Although this linker
region is not particularly well conserved, it contains two
potential caspase cleavage sites which are targets for
caspase-3 [140,141]. Cleavage of Rabaptin-5 during apo-
ptosis has been shown to prevent vesicles fusing with
endosomes, ultimately leading to fragmentation of endo-
somes and the inhibition of the endocytic pathway [140].
This is intriguing since cleavage by caspase-3 generates
two coiled-coil proteins, the C-terminal of which is still
A.K. Gillingham, S. Munro / Biochimica et Biophysica Acta 1641 (2003) 71–85 83capable of binding Rabex-5 [141], implying that binding
Rab5 and its effector protein Rabex-5 may not be the only
function of Rabaptin-5 in endosomal docking or fusion.
These results also suggest that Golgi and endosomal
membranes are fragmented during apoptosis by similar
mechanisms.8. Summary
Some common themes are emerging from studies of the
long coiled-coil proteins found in the secretory pathway, but
much remains to be resolved. Many of these proteins are
recruited to organelles by members of the Rab and Arf
families of GTPases, but if they are acting to tether vesicles
it is not yet clear how the specific binding to vesicles is
mediated. Furthermore, in the cases of p115 and EEA1, the
proteins have been suggested to participate in SNARE
complex assembly, implying that vesicle tethering could
be directly linked to downstream events. The use of large
proteins, which can act not only as initial vesicle tethers but
also as scaffolds for the assembly of other proteins required
for fusion, would seem a logical way of integrating the
processes of docking and fusion. Furthermore, one can
imagine that captured vesicles could be passed sequentially
from longer to shorter tethers bringing them closer to the
membrane surface for fusion. As well as their role in
tethering cognate vesicles, the fibrous nature of the coiled-
coil proteins could also allow them to potentially act as a
mesh that opposes those vesicles not appropriate for fusion
with a given compartment. Tethers could also play a role in
the stabilisation of organelles, as is the case with GM130
and GRASP65, which have been proposed to be compo-
nents of a Golgi matrix.
The roles discussed above for the large coiled-coil
proteins are not dissimilar to those suggested for the multi
subunit complexes, such as the exocyst, the COG complex
and TRAPP, that have also been proposed to play a role in
vesicle tethering [16]. Both sets of proteins can be recruited
to membranes by small GTPases, and both have been
suggested to interact with SNAREs. One obvious difference
is that the coiled-coil proteins have the potential to form
interactions over larger distances and thus, in the case of
vesicle tethering, could provide a kinetic enhancement to
membrane fusion by trapping vesicles in the vicinity of
other factors that make a thermodynamic contribution to
fusion. Another difference is that the coiled-coil proteins do
not generally form stable interactions with other proteins,
unlike the components that make up the multisubunit com-
plexes, but rather they appear to rely upon labile or low
affinity interactions. This may indicate that the coiled-coil
proteins are more suited to forming transient reversible
interactions to mediate the initial stages of vesicle tethering
or to allow organelles to have highly defined and yet
dynamic structures. What seems certain, however, is that
further investigation of the role of coiled-coil proteins inmembrane traffic will reveal much that is interesting and
surprising.References
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